Kenvue에 대한 매도 수량은 투자자에게 Kenvue의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Kenvue (NYSE:KVUE) 주식, 공매도 수량 보고

Kenvue

Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Equities

News

Markets

AVGO

KVUE

MRVL

NVDA

QRVO

RIOT

SWKS

행동주의 투자자 스타보드 밸류 LP는 목요일(16일) 코보(NASDAQ:QRVO)의 지분 7.7%를 인수한 것응로 알려졌다. 운영 변경을 위한 잠재적인 타깃으로 부진한 반도체 제조업체를 겨냥한 것이다.

코보, 행동주의 투자자 스타보드의 지분 취득 소식 이후 시간외 거래 7%↑

행동주의 투자자인 스타보드 밸류(Starboard Value)는 타이레놀(Tylenol) 및 리스테린(Listerine)과 같은 인기 소비자 제품을 생산하는 회사인 켄뷰(NYSE:KVUE)의 상당한 지분을 인수한 것으로 알려졌다.

타이레놀과 리스테린 제조업체 켄뷰는 스타보드 밸류의 지분 투자로 행동주의 투자자들이 주목

ABNB

ACGL

AXON

BBWI

CRWD

DLTR

ETSY

FTNT

GDDY

INTC

MPWR

MRNA

SBUX

SMCI

UBER

8월에는 주식 시장이 7월 중순 정점 이후 겪은 손실을 만회했으며, 이는 실적과 양호한 데이터가 반등에 도움이 되었다. 8월을 뒤로 보내면서 시장 성과를 더욱 폭넓게 측정하는 S&amp;P 500 지수의 상승주와 하락주를 살펴보겠다.

8월 S&amp;P 500의 상위 상승주와 하락주: 매그 7종목은 빠지고, 사이버 보안 2종목 포함

Kenvue Inc

Deutsche Bank analyst Sidney Ho maintains KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) with a Buy and raises the price target from $725 to $850.

Price Target

Analyst Ratings

KLAC

Deutsche Bank Maintains Buy on KLA, Raises Price Target to $850

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and raises the price target from $180 to $190.

AXSM

HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $190

Needham analyst Quinn Bolton reiterates Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Intelto Hold

B of A Securities analyst Jason Kupferberg maintains Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Neutral and raises the price target from $331 to $363.

B of A Securities Maintains Neutral on Visa, Raises Price Target to $363

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Benjamin Hartford downgraded the rating for United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) from Outperform to Neutral and lowered the price target from $160 to $130. UPS shares closed at $114.90 on Thursday. <a href="https://www.benzinga.com/quote/UPS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Neil Mehta downgraded Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) from Neutral to Sell and slashed the price target from $54 to $45. Occidental Petroleum shares closed at $48.92 on Thursday. <a href="https://www.benzinga.com/quote/OXY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Michael Lavery downgraded the rating for The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) from Neutral to Underweight and cut the price target from $153 to $120. Hershey shares closed at $152.14 on Thursday. <a href="https://www.benzinga.com/quote/HSY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Jessica Reif Cohen downgraded Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) from Buy to Neutral and lowered the price target from $50 to $38. Comcast shares closed at $33.25 on Thursday. <a href="https://www.benzinga.com/quote/CMCSA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Neal Dingmann downgraded the rating for Murphy Oil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) from Buy to Hold and lowered the price target from $42 to $31. Murphy Oil shares closed at $27.47 on Thursday. <a href="https://www.benzinga.com/quote/MUR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying OXY stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43335398/wall-streets-most-accurate-analysts-spotlight-on-3-risk-off-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Risk Off Stocks Delivering High-Dividend Yields</a></li>
</ul>

Downgrades

Pre-Market Outlook

Trading Ideas

CMCSA

This Occidental Petroleum Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) with a Buy and maintains $110 price target.

HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target

B of A Securities analyst Ken Hoexter maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a Buy and lowers the price target from $150 to $133.

B of A Securities Maintains Buy on United Parcel Service, Lowers Price Target to $133

Needham analyst Joseph Stringer reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Hold to Hold.

VRTX

Needham Reiterates Hold on Vertex Pharmaceuticalsto Hold

23andMe Holding Released New Polygenic Risk Score Report On The Genetics Of Osteoporosis For 23andMe+ Premium Members

WIIM

ABBV

AbbVie shares are trading higher following better-than-expected Q4 financial results.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Mind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) with a Buy and maintains $55 price target.

MNMD

HC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $55 Price Target

A new player in the AI arena, DeepSeek, has unveiled an open-source language model, R1, that experts say is a game-changer in efficiency, raising questions about the <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43244653/bitcoin-ethereum-solana-crash-heres-why-chinas-low-cost-ai-model-deepseek-may-be-to-blame">future of AI development.</a>
<h2 class="wp-block-heading">The DeepSeek Effect</h2>
Developed for under $6 million, DeepSeek&#8217;s R1 has not only outperformed established competitors in several tests but has also called into question the established big-spending approach prevalent in Silicon Valley. 
This development has triggered a mix of optimism about democratized AI and fears of an AI stock bubble bursting, sending ripples throughout financial markets.
&#8220;Another DeepSeek is hiding in plain sight,&#8221; said Roi Ginat, CEO of Endless AI, a multimodal AI company, highlighting DeepSeek's influence in making impactful AI with limited resources. 
Ginat&#8217;s own company, EndlessAI, has been working on efficient video processing, echoing DeepSeek's stand to using LLMs in practical, cost-effective ways. 
Ginat told Benzinga that EndlessAI provides the tools to make existing models work smarter by using proprietary video transfer optimization which enables massive cost reduction for video processing, adding that this is complementary, not competitive, with what DeepSeek is doing.
Speaking with Benzinga, Satya Nitta, CEO of Emergence AI, an AI orchestration company, echoed the sentiment, calling DeepSeek R1 a &#8220;meaningful advance in broadening access to AI reasoning.&#8221; 
Nitta emphasized the importance of open-source solutions that are not only trusted but also scalable and adaptable to evolving needs.
Matthew Putman, CEO of Nanotronics, an industrial AI company, told Benzinga that DeepSeek&#8217;s achievement demonstrates that &#8220;it is possible to do more with less,&#8221; suggesting that resource constraints may fuel innovation. 
Putman sees these developments as essential for broader adoption of AI for industries beyond just text generation, stressing it's critical for advancing semiconductor production, which makes AI technology possible.
Mitesh Agrawal, CEO of Positron, an AI hardware company, pointed to DeepSeek&#8217;s success as evidence that &#8220;inference-time compute is the new scaling factor&#8221; in AI development, delivering real results with optimized systems. 
Agrawal told Benzinga that performance per dollar and performance per watt are critical to make the best AI models accessible.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43356514/helix-debuts-ai-index-perpetual-market">Helix Debuts AI Index Perpetual Market, Bridging Crypto And Traditional Equities On-Chain</a>
<h2 class="wp-block-heading">Is DeepSeek A Cause For Concern?</h2>
However, concerns also accompany this disruptive innovation.
Speaking with Benzinga, Pukar Hamal, CEO of SecurityPal, an AI-enhanced security review company, warned about the security and regulatory implications of an "open-source" model with unknown alignment. 
Hamal highlighted the &#8220;gas law&#8221; of computing, whereby cheaper compute expands markets, but also stressed the need for guardrails to protect the public and maintain compliance.
These concerns translated into market jitters on the day DeepSeek news first broke.
The Nasdaq Composite dropped 2.7% on Monday, the S&amp;P 500 slid 1.6% and the Dow Jones Industrial Average dipped 0.1% following the DeepSeek announcement.
The announcement of a new low-cost, high-performance open source AI model that competes with existing proprietary AI systems also drove volatility in the cryptocurrency market. 
Crypto markets also took a hit, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) falling 5.5% and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) dropping 7% on Monday before recovering.
Other major altcoins also experienced significant losses, as traders grappled with the potential implications of DeepSeek&#8217;s emergence.
On Monday, altcoins like Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), BNB (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>), Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) were down 11%, 3.5%, 9% and 8.5%, respectively.
<h2 class="wp-block-heading">What&#8217;s Next For DeepSeek</h2>
DeepSeek's disruptive impact is already rippling through financial markets. 
The sharp declines in AI-related stocks and cryptocurrencies suggest that investors are reassessing the sustainability of current AI valuations. 
Analysts warn that DeepSeek's ability to deliver high-performance AI at a fraction of traditional costs may force industry leaders to rethink their strategies.
Moreover, experts believe DeepSeek's approach could reshape the $25 billion computer vision market and redefine the scalability of AI applications. 
As companies continue to push the boundaries of multimodal AI, the industry appears poised for a shift toward leaner, more efficient AI models that can thrive outside the confines of billion-dollar research labs.
In the face of this transformation, the question remains: will legacy AI firms adapt to the new paradigm, or will DeepSeek's breakthrough mark the beginning of a broader industry upheaval?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43351797/grayscale-seeks-sec-approval-to-convert-xrp-trust-into-exchange-traded-fund">Grayscale Seeks SEC Approval To Convert XRP Trust Into Exchange-Traded Fund</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BNB

$BTC

$DOGE

$ETH

$SOL

Experts Say DeepSeek Proves High-Performance AI Possible Without Silicon Valley's Spending

Guidance

AbbVie Sees FY25 Adj. EPS $12.12-$12.32 vs $10.08 Est.; Reaffirms Long-Term Revenue Growth Outlook of High Single-Digit CAGR Through 2029

YMAB

Y-mAbs Therapeutics Says It Will Present Preclinical And Translational Pharmacokinetics Data Of GD2-SADA In A Poster At Society Of Nuclear Medicine & Molecular Imaging Mid-winter And American College Of Nuclear Medicine Annual Meeting

Hitachi (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HTHIY#OTC">HTHIY</a>) reported its Q3 earnings results on Friday, January 31, 2025 at 07:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Hitachi missed estimated earnings by -9.0%, reporting an EPS of $0.4 versus an estimate of $0.44.
Revenue was up $903.00 million from the same period last year.
<h3>Historical Earnings Summary</h3>
In the previous quarter, the company missed on EPS by $0.07, resulting in a 5.0% increase change in the share price the following day.
Here's a look at Hitachi's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.41</td>
<td>0.05</td>
<td>0.33</td>
<td>0.34</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.34</td>
<td>0.49</td>
<td>1.02</td>
<td>0.64</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>15.82B</td>
<td>12.27B</td>
<td>15.53B</td>
<td>13.49B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>15.68B</td>
<td>14.19B</td>
<td>18.68B</td>
<td>15.28B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Hitachi management provided guidance for FY 2024, expecting earnings between $0.91 and $0.91 per share.
To track all earnings releases for Hitachi <a href="https://www.benzinga.com/quote/HTHIY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

HTHIY

Earnings Summary: Hitachi Q3

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported quarterly earnings of $2.16 per share which beat the analyst consensus estimate of $2.11 by 2.37 percent. This is a 22.58 percent decrease over earnings of $2.79 per share from the same period last year. The company reported quarterly sales of $15.102 billion which beat the analyst consensus estimate of $14.827 billion by 1.85 percent. This is a 5.60 percent increase over sales of $14.301 billion the same period last year.

Earnings Beats

AbbVie Q4 2024 Adj. EPS $2.16 Beats $2.11 Estimate, Sales $15.102B Beat $14.827B Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) with a Buy and maintains $9 price target.

LCTX

HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

First BanCorp. Reveals Strategic Reorganization Aligned With Corporate Succession Plan Aimed At Improving Operational Efficiency, Enhancing Customer Experience, And Driving Business Transformation To Align Resources For Growth

HC Wainwright &amp; Co. analyst Edward White reiterates Valneva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) with a Buy and maintains $18 price target.

VALN

HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $18 Price Target

Samsung Electronics Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) <a target="_blank" href="https://www.benzinga.com/topic/samsung" rel="noreferrer noopener">reported fourth-quarter revenue</a> growth of 12% year-on-year to 75.8 trillion Korean won ($52.2 billion).
Operating profit declined by 30% Q/Q to 6.5 trillion Korean won due to soft market conditions, especially for IT products, and higher R&amp;D expenditures.
The DS Division (encompassing Memory and S.LSI / Foundry) posted 30.1 trillion Korean won in revenue (versus 21.7 trillion Korean won Y/Y) backed by a higher blended DRAM average selling price (ASP) due to the increased sales of high-bandwidth memory (HBM) and high-density <a target="_blank" href="https://www.samsung.com/global/ir/financial-information/earnings-release/" rel="noreferrer noopener">DDR5 for servers</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43165472/samsung-taps-google-ai-qualcomm-tech-for-galaxy-s25-to-rival-apples-iphone" rel="noreferrer noopener">Samsung Taps Google AI, Qualcomm Tech for Galaxy S25 to Rival Apple&#8217;s iPhone</a>
The division reported 2.9 trillion Korean won in operating profit (versus a loss of (2.2) trillion Korean won Y/Y).
Samsung Display Corp Division, posted 8.1 trillion Korean won in revenue (versus 9.7 trillion Korean won Y/Y). The division reported 0.9 trillion Korean won in operating profit (versus 2.0 trillion Korean won Y/Y) due to sluggish smartphone demand and rising competition for the mobile display business.
The Mobile eXperience (MX) and Networks businesses posted 25.8 trillion Korean won in revenue (versus 25.0 Korean won Y/Y). The division reported 2.1 trillion Korean won in operating profit (versus 2.7 trillion Korean won Y/Y).
The quarterly capex was 17.8 trillion Korean won, with 16 trillion Korean won allocated to the DS Division and 1 trillion Korean won to SDC.
While overall earnings improvement may be limited in the first quarter of 2025 due to weakness in the semiconductors business, the company aims to pursue growth through increased sales of smartphones with differentiated AI experiences and premium products in the Device eXperience (DX) Division.
For 2025, the company plans to enhance technological and product advantages in AI, meet future demand for high-value-added products, and drive sales growth in premium segments.
Samsung, in a preliminary earnings report, flagged sluggish demand for conventional chips used in personal computers and mobile phones weighed on its memory business, with earnings also dented by rising R&amp;D costs and early investments in expanding advanced-chip processing capability, the Wall Street Journal <a target="_blank" href="https://www.wsj.com/business/earnings/samsungs-net-profit-beats-consensus-but-chip-woes-weigh-cad40447?mod=tech_lead_pos1" rel="noreferrer noopener">reports</a>.
SK Hynix has left Samsung behind in HBM, Eric Ross of Cascend Securities, <a target="_blank" href="https://www.cnbc.com/2025/01/31/samsung-fourth-quarter-profit-falls-short-of-estimates-as-ai-demand-remains-strong.html" rel="noreferrer noopener">told</a> CNBC. Micron Technology, Inc also gained ground, Ross told. PC and smartphone DRAM markets are under price pressure, he added.
Nabila Popal of IDC told CNBC that Samsung&#8217;s share of the premium market has inched closer to market leader Apple Inc thanks to the former&#8217;s Galaxy S24 series featuring Galaxy AI.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/media/25/01/43352019/amazon-cuts-more-jobs-in-cost-saving-push-report" target="_blank" rel="noreferrer noopener">Amazon Cuts More Jobs in Cost-Saving Push: Report</a></li>
</ul>
Image via Shutterstock.

Media

SSNLF

Samsung Q4 Earnings: 12% Revenue Growth, Closes Gap With Apple In Premium Phones, Eyes AI-Powered Growth In 2025

UBS lowered the firm's price target on Kenvue (KVUE) to $23 from $24 and keeps a Neutral rating on the shares. Sentiment around Consumer Staples is...

Kenvue price target lowered to $23 from $24 at UBS

In a report released today, Lauren Lieberman from Barclays maintained a Hold rating on Kenvue, Inc. (KVUE – Research Report), with a price target o...

Kenvue, Inc. (KVUE) Receives a Hold from Barclays

Barclays analyst Lauren Lieberman lowered the firm's price target on Kenvue (KVUE) to $21 from $23 and keeps an Equal Weight rating on the shares a...

Kenvue price target lowered to $21 from $23 at Barclays

BofA's best financial, consumer stock ideas for 2025: WFC, SBUX, more

Top SA quant-rated consumer staples before Q4 frenzy - Philip Morris, Clorox

What Can The Dividend Kings Deliver In 2025?

Consumer staples stocks catch a bid as AI anxiety leads to risk-off trading

Dividends and growth: SA spotlights 13 names offering both

Tracking Yacktman Asset Management Portfolio - Q4 2024 Update

Barclays analyst Lauren Lieberman maintained a Hold rating on Kenvue, Inc. (KVUE – Research Report) today and set a price target of $21.00. The com...

Barclays Remains a Hold on Kenvue, Inc. (KVUE)

BOIVF

BRBR

BYND

CBSH

CDUAF

CINF

COST

COTY

CTSH

DGRO

FANG

FMCB

FOXA

FSTA

GOOG

GOOGL

HAIN

INGR

KNTK

LANC

MDLZ

MNST

MSEX

MSFT

NDSN

NOBL

NWSA

NWSAL

PRMB

ROST

SCHD

SCHG

SCHW

SPGI

SPYG

UBSI

UHAL

UPRO

VICI

VONG

WELL

WFCNP

Press Releases

Kenvue Announces Participation in the Barclays Global Consumer Staples Conference

Kenvue Drives Climate Action Strategy Forward

Kenvue Declares Quarterly Cash Dividend

Kenvue to Announce Third Quarter 2024 Results on November 7, 2024

Starboard Value Issues Presentation Delivered at 13D Monitor's 2024 Active-Passive Investor Summit

Neutrogena® Launches Breakthrough Collaboration with Two of World's Most Recognizable Dermatologists

Kenvue Reports Third Quarter 2024 Results

Kenvue Announces Participation in the Morgan Stanley Global Consumer & Retail Conference

Kenvue to Announce Fourth Quarter and Full Year 2024 Results on February 6, 2025

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Honest Co

Interparfums

Lifevantage

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Enter

The Beauty Health Company - Class A Common Stock

Beauty Health

United-Guardian

Unilever

Usana Health Sciences

Veru

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Yatsen Holding

Comments

Kenvue

매도 수량

Kenvue (NYSE:KVUE) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌